- Home
- BVN vs ACAD Comparison
BVN vs ACAD Comparison
Compare BVN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVN
- ACAD
- Stock Information
- Founded
- BVN 1953
- ACAD 1993
- Country
- BVN Peru
- ACAD United States
- Employees
- BVN N/A
- ACAD N/A
- Industry
- BVN Metal Mining
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- BVN Basic Materials
- ACAD Health Care
- Exchange
- BVN Nasdaq
- ACAD Nasdaq
- Market Cap
- BVN 3.3B
- ACAD 2.9B
- IPO Year
- BVN 1996
- ACAD 2004
- Fundamental
- Price
- BVN $12.68
- ACAD $16.68
- Analyst Decision
- BVN Buy
- ACAD Buy
- Analyst Count
- BVN 2
- ACAD 18
- Target Price
- BVN $16.50
- ACAD $26.53
- AVG Volume (30 Days)
- BVN 986.6K
- ACAD 1.7M
- Earning Date
- BVN 10-30-2024
- ACAD 11-06-2024
- Dividend Yield
- BVN 0.58%
- ACAD N/A
- EPS Growth
- BVN 329.23
- ACAD N/A
- EPS
- BVN 1.41
- ACAD 0.78
- Revenue
- BVN $1,108,813,000.00
- ACAD $929,236,000.00
- Revenue This Year
- BVN N/A
- ACAD $37.34
- Revenue Next Year
- BVN N/A
- ACAD $7.25
- P/E Ratio
- BVN $8.76
- ACAD $21.73
- Revenue Growth
- BVN 35.82
- ACAD 47.06
- 52 Week Low
- BVN $11.61
- ACAD $14.15
- 52 Week High
- BVN $18.84
- ACAD $32.59
- Technical
- Relative Strength Index (RSI)
- BVN 50.56
- ACAD 48.24
- Support Level
- BVN $12.25
- ACAD $16.27
- Resistance Level
- BVN $13.50
- ACAD $17.86
- Average True Range (ATR)
- BVN 0.45
- ACAD 0.78
- MACD
- BVN 0.02
- ACAD -0.13
- Stochastic Oscillator
- BVN 43.45
- ACAD 20.62
About BVN Buenaventura Mining Company Inc.
Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.